Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Cardiac amyloidosis
1
Department of Cardiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
Corresponding author
Małgorzata Niemiec
Klinika Kardiologii, Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach, ul. Ziołowa 45/47, 40-635 Katowice
Klinika Kardiologii, Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach, ul. Ziołowa 45/47, 40-635 Katowice
Ann. Acad. Med. Siles. 2024;78:146-154
KEYWORDS
TOPICS
ABSTRACT
Amyloidosis is a rare disease characterized by an abnormal accumulation of the amyloid protein in tissues. Amyloidosis can be divided into two main subtypes: transthyretin amyloidosis (ATTR-CA) and immunoglobulin light chain amyloidosis (AL-CA). Accumulation of the amyloid protein in the heart muscle may lead to conduction disturbances, restrictive cardiomyopathy, and consequently, heart failure. The symptoms may include decreased exercise tolerance, shortness of breath, swelling and fainting. The diagnosis is based on laboratory tests, imaging and biopsy. Treatment focuses mainly on slowing the progression of the disease and treating the symptoms.
CONFLICT OF INTEREST
None declared.
REFERENCES (50)
1.
Benson M.D., Buxbaum J.N., Eisenberg D.S., Merlini G., Saraiva M.J.M., Sekijima Y. et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25(4): 215–219, doi: 10.1080/13506129.2018.
2.
Kumar S.K., Gertz M.A., Lacy M.Q., Dingli D., Hayman S.R., Buadi F.K. et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin. Proc. 2011; 86(1): 12–18, doi: 10.4065/mcp.2010.0480.
3.
Kyle R.A., Larson D.R., Kurtin P.J., Kumar S., Cerhan J.R., Therneau T.M. et al. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin. Proc. 2019; 94(3): 465–471, doi: 10.1016/j.mayocp.2018.08.041.
4.
Pinney J.H., Whelan C.J., Petrie A., Dungu J., Banypersad S.M., Sattianayagam P. et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J. Am. Heart Assoc. 2013; 2(2): e000098, doi: 10.1161/JAHA.113.000098.
5.
Grogan M., Scott C.G., Kyle R.A., Zeldenrust S.R., Gertz M.A., Lin G. et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J. Am. Coll. Cardiol. 2016; 68(10): 1014–1020, doi: 10.1016/j.jacc.2016.06.033.
6.
Jacobson D.R., Alexander A.A., Tagoe C., Buxbaum J.N. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid 2015; 22(3): 171–174, doi: 10.3109/13506129.2015.1051219.
7.
González-López E., Gallego-Delgado M., Guzzo-Merello G., de Haro-Del Moral F.J., Cobo-Marcos M., Robles C. et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J. 2015; 36(38): 2585–2594, doi: 10.1093/eurheartj/ehv338.
8.
Castano A., Narotsky D.L., Hamid N., Khalique O.K., Morgenstern R., DeLuca A. et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur. Heart J. 2017; 38(38): 2879–2887, doi: 10.1093/eurheartj/ehx350.
9.
Falk R.H., Alexander K.M., Liao R., Dorbala S. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J. Am. Coll. Cardiol. 2016; 68(12): 1323–1341, doi: 10.1016/j.jacc.2016.06.053.
10.
Brenner D.A., Jain M., Pimentel D.R., Wang B., Connors L.H., Skinner M. et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ. Res. 2004; 94(8): 1008–1010, doi: 10.1161/01.RES.0000126569.75419.74.
11.
Gertz M.A., Comenzo R., Falk R.H., Fermand J.P., Hazenberg B.P., Hawkins P.N. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am. J. Hematol. 2005; 79(4): 319–328, doi: 10.1002/ajh.20381.
12.
Bhuiyan T., Helmke S., Patel A.R., Ruberg F.L., Packman J., Cheung K. et al. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin. Circ. Heart Fail. 2011; 4(2): 121–128, doi: 10.1161/CIRCHEARTFAILURE.109.910455.
13.
Longhi S., Quarta C.C., Milandri A., Lorenzini M., Gagliardi C., Manuzzi L. et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid 2015; 22(3): 147–155, doi: 10.3109/13506129.2015.1028616.
14.
El-Am E.A., Dispenzieri A., Melduni R.M., Ammash N.M., White R.D., Hodge D.O. et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J. Am. Coll. Cardiol. 2019; 73(5): 589–597, doi: 10.1016/j.jacc.2018.10.079.
15.
Palma J.A., Gonzalez-Duarte A., Kaufmann H. Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management. Clin. Auton. Res. 2019; 29(suppl 1): 33–44, doi: 10.1007/s10286-019-00623-x.
16.
Scully P.R., Treibel T.A., Fontana M., Lloyd G., Mullen M., Pugliese F. et al. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J. Am. Coll. Cardiol. 2018; 71(4): 463–464, doi: 10.1016/j.jacc.2017.11.037.
17.
Kristen A.V., Dengler T.J., Hegenbart U., Schonland S.O., Goldschmidt H., Sack F.U. et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008; 5(2): 235–240, doi: 10.1016/j.hrthm.2007.10.016.
18.
de Marneffe N., Dulgheru R., Ancion A., Moonen M., Lancellotti P. Cardiac amyloidosis: a review of the literature. Acta Cardiol. 2022; 77(8), 683–692, doi: 10.1080/00015385.2021.1992990.
19.
Ng P.L.F., Lim Y.C., Evangelista L.K.M., Wong R.C.C., Chai P., Sia C.H. et al. Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis. Ann. Noninvasive Electrocardiol. 2022; 27(4): e12967, doi: 10.1111/anec.12967.
20.
Ruberg F.L., Grogan M., Hanna M., Kelly J.W., Maurer M.S. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019; 73(22): 2872–2891, doi: 10.1016/j.jacc.2019.04.003.
21.
Suhr O.B., Anan I., Backman C., Karlsson A., Lindqvist P., Mörner S. et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J. Intern. Med. 2008; 263(3): 294–301, doi: 10.1111/j.1365-2796.2007.01888.x.
22.
Oghina S., Delbarre M.A., Poullot E., Belhadj K., Fanen P., Damy T. Les amyloses cardiaques: état des lieux en 2022. Rev. Med. Interne 2022; 43(9): 537–544, doi: 10.1016/j.revmed.2022.04.036.
23.
Holcman K., Kostkiewicz M., Podolec P., Rubiś P. Cardiac amyloidosis – state-of-the-art diagnosis and emerging therapies. [Article in Polish]. Folia Cardiol. 2019; 14(6): 616–624, doi: 10.5603/FC.2019.0115.
24.
Habib G., Bucciarelli-Ducci C., Caforio A.L.P., Cardim N., Charron P., Cosyns B. et al. Multimodality Imaging in Restrictive Cardiomyopathies: An EACVI expert consensus document In collaboration with the “Working Group on myocardial and pericardial diseases” of the European Society of Cardiology Endorsed by The Indian Academy of Echocardiography. Eur. Heart J. Cardiovasc. Imaging 2017; 18(10): 1090–1121, doi: 10.1093/ehjci/jex034.
25.
Phelan D., Collier P., Thavendiranathan P., Popović Z.B., Hanna M., Plana J.C. et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98(19): 1442–1448, doi: 10.1136/heartjnl-2012-302353.
26.
Gillmore J.D., Maurer M.S., Falk R.H., Merlini G., Damy T., Dispenzieri A. et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133(24): 2404–2412, doi: 10.1161/CIRCULATIONAHA.116.021612.
27.
Pan J.A., Kerwin M.J., Salerno M. Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc. Imaging 2020; 13(6): 1299–1310, doi: 10.1016/j.jcmg.2020.03.010.
28.
Patel A.R., Kramer C.M. Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc. Imaging 2017; 10(10 Pt A): 1180–1193, doi: 10.1016/j.jcmg.2017.08.005.
29.
Ioannou A., Patel R.K., Razvi Y., Porcari A., Knight D., Martinez-Naharro A. et al. Multi-imaging characterization of cardiac phenotype in different types of amyloidosis. JACC Cardiovasc. Imaging 2023; 16(4): 464–477, doi: 10.1016/j.jcmg.2022.07.008.
30.
Perugini E., Guidalotti P.L., Salvi F., Cooke R.M., Pettinato C., Riva L. et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J. Am. Coll. Cardiol. 2005; 46(6): 1076–1084, doi: 10.1016/j.jacc.2005.05.073.
31.
Ardehali H., Qasim A., Cappola T., Howard D., Hruban R., Hare J.M. et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am. Heart J. 2004; 147(5): 919–923, doi: 10.1016/j.ahj.2003.09.020.
32.
Ramaekers J., Janssens J., Waumans L., Stessens L., Dupont M., Mullens W. et al. Indications and diagnostic yield of endomyocardial biopsies for unexplained cardiomyopathy, a single center experience. Acta Cardiol. 2020; 75(2): 138–146, doi: 10.1080/00015385.2018.1561597.
33.
Hänselmann A., Berliner D., Bauersachs J., Bavendiek U. Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy. Herz 2022; 47(4): 324–331, doi: 10.1007/s00059-022-05122-w.
34.
Vrana J.A., Gamez J.D., Madden B.J., Theis J.D., Bergen H.R. 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114(24): 4957–4959, doi: 10.1182/blood-2009-07-230722.
35.
Stern L.K., Kittleson M.M. Updates in cardiac amyloidosis diagnosis and treatment. Curr. Oncol. Rep. 2021; 23(4): 47, doi: 10.1007/s11912-021-01028-8.
36.
Garcia-Pavia P., Rapezzi C., Adler Y., Arad M., Basso C., Brucato A. et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2021; 42(16): 1554–1568, doi: 10.1093/eurheartj/ehab072.
37.
Damy T., Costes B., Hagège A.A., Donal E., Eicher J.C., Slama M. et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur. Heart J. 2016; 37(23): 1826–1834, doi: 10.1093/eurheartj/ehv583.
38.
Papa R., Lachmann H.J. Secondary, AA, amyloidosis. Rheum. Dis. Clin. North Am. 2018; 44(4): 585–603, doi: 10.1016/j.rdc.2018.06.004.
39.
Oghina S., Bougouin W., Bézard M., Kharoubi M., Komajda M., Cohen--Solal A. et al. The impact of patients with cardiac amyloidosis in HFpEF trials. JACC Heart Fail. 2021; 9(3): 169–178, doi: 10.1016/j.jchf.2020.12.005.
40.
Ihne S., Morbach C., Obici L., Palladini G., Störk S. Amyloidosis in heart failure. Curr. Heart Fail. Rep. 2019; 16(6): 285–303, doi: 10.1007/s11897-019-00446-x.
41.
Rind J., Chalfoun N., McNamara R. Cardiac amyloidosis: The great masquerader. Glob. Cardiol. Sci. Pract. 2018; 2018(2): 18, doi: 10.21542/gcsp.2018.18.
42.
Vermeer A.M.C., Janssen A., Boorsma P.C., Mannens M.M.A.M., Wilde A.A.M., Christiaans I. Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy. Amyloid 2017; 24(2): 87–91, doi: 10.1080/13506129.2017.1322573.
43.
Maron B.J., Desai M.Y., Nishimura R.A., Spirito P., Rakowski H., Towbin J.A. et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2022; 79(4): 372–389, doi: 10.1016/j.jacc.2021.12.002.
44.
Tanaka H. Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: special focus on speckle-tracking longitudinal strain. J. Echocardiogr. 2021; 19(2): 71–79, doi: 10.1007/s12574-020-00508-3.
45.
Rausch K., Scalia G.M., Sato K., Edwards N., Lam A.K., Platts D.G. et al. Left atrial strain imaging differentiates cardiac amyloidosis and hypertensive heart disease. Int. J. Cardiovasc. Imaging 2021; 37(1): 81–90, doi: 10.1007/s10554-020-01948-9.
46.
Sperry B.W., Vadalia A. Primer on the differential diagnosis and workup for transthyretin cardiac amyloidosis. Am. J. Cardiol. 2022; 185(Suppl 1): S11–S16, doi: 10.1016/j.amjcard.2022.10.052.
47.
Maurer M.S., Elliott P., Comenzo R., Semigran M., Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017; 135(14): 1357–1377, doi: 10.1161/CIRCULATIONAHA.116.024438.
48.
Kyle R.A., Linos A., Beard C.M., Linke R.P., Gertz M.A., O’Fallon W.M. et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79(7): 1817–1822.
49.
Comenzo R.L. Out, out–making amyloid’s candle briefer. N. Engl. J. Med. 2015; 373(12): 1167–1169, doi: 10.1056/NEJMe1508746.
50.
Rubin J., Maurer M.S. Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu. Rev. Med. 2020; 71: 203–219, doi: 10.1146/annurev-med-052918-020140.
Share
RELATED ARTICLE
| eISSN: | 1734-025X |
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
